Vigil Neuroscience, INC

Sanofi has finalized its acquisition of Vigil Neuroscience, Inc., converting Vigil shares into cash and contingent value rights tied to the clinical candidate VG-3927.

Vigil Neuroscience, Inc. has voluntarily supplemented its definitive proxy statement for the Sanofi merger to address shareholder demands alleging material omissions, while denying the necessity of such disclosures.

A significant regulatory condition for the acquisition of Vigil Neuroscience by Sanofi has been satisfied, moving the merger closer to completion.

Vigil Neuroscience, Inc. announced that its stockholders approved the election of two Class I directors and ratified PricewaterhouseCoopers LLP as its independent auditor for 2025 at the Annual Meeting held on May 22, 2025.

Sanofi will acquire Vigil Neuroscience for $8.00 per share in cash, plus a contingent value right of $2.00 per share, potentially totaling $600 million, to enhance its neurology and immunology focus.

Vigil Neuroscience announces its Q1 2025 financial results and provides updates on its clinical programs, including plans to initiate a Phase 2 trial for VG-3927 in Alzheimer's disease and report final analysis from the IGNITE Phase 2 trial for iluzanebart in ALSP.

Vigil Neuroscience reports Q2 2025 results, highlighting progress on its acquisition by Sanofi for $8.00 cash plus a $2.00 CVR per share, while discontinuing its iluzanebart clinical program due to lack of efficacy.

Vigil Neuroscience reports a net loss of $22.4 million for Q1 2025 while advancing clinical trials for iluzanebart and VG-3927.

Vigil Neuroscience's third quarter 2024 report details ongoing clinical trials, financial status, and strategic developments in their neurodegenerative disease programs.

Vigil Neuroscience announced its Q2 2024 financial results, highlighting progress in clinical trials and a significant $40 million investment from Sanofi.

Vigil Neuroscience reports a net loss of $19.94 million for the first quarter of 2024, while advancing its clinical programs for neurodegenerative diseases.

Vigil Neuroscience's 10-K filing highlights the company's ongoing clinical trials for neurodegenerative diseases and its financial position.

Vigil Neuroscience, a clinical-stage biotech company, released its 2023 annual report, highlighting progress in its neurodegenerative disease programs and ongoing clinical trials.

Atlas Venture entities disposed of their shares in Vigil Neuroscience, Inc. as part of its merger with Sanofi, receiving $8.00 cash plus a $2.00 contingent value right per share.

Vigil Neuroscience, Inc. director Mary Thistle reports disposal of shares and options following the company's acquisition by Sanofi for $8.00 cash plus a $2.00 CVR per share.

Vigil Neuroscience's Chief Medical Officer, Petra Kaufmann, converted her stock options into cash and contingent value rights following the company's merger with Sanofi.

A Form 4 filing reveals Vigil Neuroscience Director Samantha L. Budd Haeberlein's equity disposition following the company's merger with Sanofi.

Vigil Neuroscience's CFO, Jennifer Lynn Ziolkowski, disposed of all her common stock and stock options following the company's acquisition by Sanofi on August 5, 2025.

Vigil Neuroscience, Inc. has been acquired by Sanofi, converting shares and options into cash and contingent value rights.

Vigil Neuroscience, Inc. announced the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, a significant step towards its acquisition by Sanofi.

Vigil Neuroscience, a clinical-stage biotechnology company, has entered into a definitive merger agreement to be acquired by Sanofi for $8.00 per share in upfront cash plus a contingent value right of $2.00 per share, contingent on the achievement of a key clinical milestone for VG-3927.

Vigil Neuroscience and Sanofi have entered into a merger agreement where Sanofi will acquire Vigil, pending stockholder and regulatory approvals.

Vigil Neuroscience is set to be acquired by Sanofi, aiming to advance TREM2 agonist program for Alzheimer's disease and returning VGL101 to Amgen.

Sanofi is set to acquire Vigil Neuroscience for $8.00 per share in cash upfront, plus a contingent value right (CVR) of up to $2.00 per share, pending regulatory and stockholder approvals, with the transaction expected to close in the third quarter of 2025.

Sanofi is set to acquire Vigil Neuroscience in a deal valued at up to $600 million, gaining access to Vigil's TREM2 agonist pipeline, including the Phase 2-ready candidate VG-3927 for Alzheimer's disease.

Vigil Neuroscience, Inc. has been acquired by Sanofi, with shareholders receiving $8.00 cash plus a $2.00 contingent value right per share.

Vida Ventures, through its entities Vida Ventures III, L.P. and Vida Ventures III-A, L.P., has significantly reduced its beneficial ownership in Vigil Neuroscience, Inc. by selling over 1.2 million shares of common stock for approximately $9.5 million.

Vida Ventures, a key institutional investor, has filed an Amendment No. 2 to its Schedule 13D, disclosing a substantial reduction in its beneficial ownership of Vigil Neuroscience, Inc. common stock.

Northpond Ventures and its affiliates have reported the sale of their entire beneficial ownership in Vigil Neuroscience, Inc., effective May 22, 2025, no longer holding more than five percent of the company's common stock.

Beryl Capital Management and its affiliates have fully divested their beneficial ownership in Vigil Neuroscience, Inc., reporting 0% ownership.

Biotechnology Value Fund and its affiliates have fully divested their beneficial ownership in Vigil Neuroscience, Inc. as of June 30, 2025.

Glazer Capital, LLC and Paul J. Glazer report beneficial ownership of 6.45% of Vigil Neuroscience, Inc.'s common stock.

Glazer Capital, LLC and Paul J. Glazer have reported a 5.39% beneficial ownership stake in Vigil Neuroscience, Inc. common stock, held for investment purposes.

Beryl Capital Management and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in Vigil Neuroscience, Inc., totaling 4,606,267 shares of common stock.

A group of investment entities led by Biotechnology Value Fund and Mark N. Lampert has filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.99% in Vigil Neuroscience, Inc. as of March 31, 2025.